38,997 Novo Nordisk A/S $NVO Shares Sold by Private Advisory Group LLC

Private Advisory Group LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 294,615 shares of the company’s stock after selling 38,997 shares during the period. Private Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $11,169,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. CoreCap Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock valued at $256,000 after purchasing an additional 242 shares during the last quarter. Claro Advisors Inc. increased its holdings in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Claro Advisors Inc. now owns 21,868 shares of the company’s stock worth $829,000 after buying an additional 256 shares during the last quarter. Carson Advisory Inc. increased its holdings in shares of Novo Nordisk A/S by 2.2% during the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock worth $453,000 after buying an additional 268 shares during the last quarter. Byrne Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company’s stock worth $114,000 after buying an additional 270 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT boosted its holdings in Novo Nordisk A/S by 0.6% in the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after acquiring an additional 272 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

More Novo Nordisk A/S News

Investors following NVO have been watching these news items:

• Positive Sentiment: Wegovy pill sales reached DKK 5.4 billion in the third quarter, and prescriptions for Novo’s weight-loss drugs reportedly topped eight million. The results support Novo’s strategy of growing sales through higher treatment volume, although the company remains in a transition period. Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
• Positive Sentiment: BMO raised its price target for NVO, offering support for the shares, though the article describes technical signals as mixed. Novo Nordisk Stock Price Prediction: BMO’s Higher Target Meets a Mixed Technical Tape
• Neutral Sentiment: Novo signed DJ Khaled as a Wegovy ambassador, with plans for him to share his weight-management experience and routine. The campaign may raise awareness, but its sales impact is uncertain. Novo and DJ Khaled Team Up to Take Fans Behind the Scenes

Novo Nordisk A/S Stock Down 1.0%

Shares of Novo Nordisk A/S stock opened at $40.66 on Friday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a market capitalization of $181.56 billion, a PE ratio of 10.24, a P/E/G ratio of 1.41 and a beta of 0.70. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.84 and a quick ratio of 0.64. The business has a 50-day moving average of $40.20 and a 200-day moving average of $43.44.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on NVO shares. Cfra lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective on the stock. in a research note on Tuesday, September 22nd. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Deutsche Bank reissued a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. Jefferies Financial Group restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $59.44.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.